Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current anti-dsDNA antibody status.
Methods
Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann–Whitney test, chi square, and linear regression analyses.
Results
Mean (SD) age of the patients was 44.9 ± 12.7 years; SLEDAI (mean ± SD) was 3.4 ± 4.0. Serum lambda FLC levels had a moderate correlation (r = 0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r = 0.48) and SLEDAI (r = 0.52) was better than of current dsDNA antibody status with PGA (r = 0.33) and adjusted SLEDAI (r = 0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31% of variance in SLEDAI scores.
Conclusion
Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.
HopperJEPapagiannesE. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol1986; 101: 122–131.
2.
HopperJESequeiraWMartellottoJ. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light chain immunoglobulin. J Clin Immunol1989; 9: 338–350.
3.
AggarwalRSequeiraWKokebieR. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken)2011; 63: 891–898.
4.
JollyMAggarwalRFrancisS. Serum free light chains and disease activity in systemic lupus erythematosus. Hematol Rep2010; 2(s2): 45–45.
5.
GuillemetteTBardinNCournacJ. Serum free light chain levels as a marker of disease activity following treatment with B cell depletion in systemic lupus erythematosus. Hematol Rep2010; 2(s2): 44–44.
6.
MosmannTRCherwinskiHBondMW. Two types of murine helper T cell clones: definition according to profiles of lymphokines and secreted proteins. J Immunol1986; 136: 2348–2357.
7.
AkahoshiMNakashimaHTanakaY. Th1/Th2 balance of peripheral T cells in SLE. Arthritis Rheum1999; 42: 1644–1648.
8.
IshidaHMuchamuelTSakaguchiS. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W mice. J Exp Med1994; 179: 305–310.
9.
RackeMKBonomoAScottDE. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med1994; 180: 1961–1966.
10.
TakahashiSFossatiLIwamotoM. Imbalance towards Th1 predominance is associated with acceleration of lupus like autoimmune syndrome in MRl mice. J Clin Invest1996; 97: 1597–1604.
11.
DayanMSegalRMozesE. Cytokine manipulation by methotrexate treatment in murine experimental SLE. J Rheumatol1997; 24: 1075–1082.
12.
KishimotoTHiranoT. Molecular regulation of the B cell lymphocyte response. Annu Rev Immunol1988; 6: 485–512.
13.
Van SnickJ. Interleukin-6: an overview. Annu Rev Immunol1990; 8: 253–278.
14.
NagafuchiHSuzukiNMizushimaY. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol1993; 151: 6525–6534.
15.
KawanoMMMiharaKHuangN. Differentiation of early plasma cells on bone marrow stromal cells requires IL-6 for escaping from apoptosis. Blood1995; 85: 487–494.
16.
Linker-IsraeliMDeansRJWallaceDJ. Elevated levels of endogenous IL-6 in systemic lupus erythematosus – a putative role in pathogenesis. J Immunol1991; 147: 117123–123.
17.
SuhCHKimHA. Cytokines and their receptors as biomarkers for systemic lupus erythematosus. Expert Rev Mol Diagn2008; 8: 189–198.
18.
ChunHYChungJWKimHA. Cytokine IL-6 and IL-10 as biomarkers in SLE. J Clin Immunol2007; 27: 461–466.
19.
MooreKWO’GarraAMalefytRW. Interleukin 10. Annu Rev Immunol1993; 11: 165–190.
20.
FirentinoDFBondMWMosmannTR. Two types of mouse T helper cells. IV TH2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med1989; 170: 2081–2095.
21.
HsuDHMooreKWSpitsH. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-γ synthesis and lymphokine activated killer activity. Int Immunol1992; 4: 563–569.
22.
RoussetFGarciaEDefranceT. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA1992; 89: 1890–1893.
23.
ViallardJFPellegrinJLRanchinV. Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol1999; 115: 189–195.
24.
BlancoPPaluckaAKGillM. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science2001; 294: 1540–1543.
25.
SiegalFPKadowakiNShodellM. The nature of the principal type 1 interferon-producing cells in human blood. Science1999; 284: 1835–1837.
26.
KirouKALeeCGeorgeS. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum2005; 52: 1491–1503.
27.
NiewoldTBHuaJLehmanTJ. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun2007; 8: 492–502.
28.
KariukiSNNiewoldTB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res2010; 155(3): 109–117.
29.
KariukiSNFranekBSKumarAA. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther2010; 12: R151–R151.
30.
BaechlerECBatliwallaFMKarypisG. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA2003; 100: 2610–2615.
31.
PetriMSinghSTesfasyoneH. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 200918: 980–989.
32.
Landolt-MarticorenaCBonventiGLubovichA. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis2009; 68: 1440–1446.
33.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
34.
BombardierCGladmanDDUrowitzMB. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum1992; 35: 630–640.
35.
KatzmannJAClarkRJAbrahamRS. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem2002; 48: 1437–1444.
HuaJKirouKLeeCCrowMK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum2006; 54: 1906–1916.
38.
MetsärinneKPNordströmDCKonttinenYT. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int1992; 12: 93–96.
39.
SwaakAJRooyenAAardenLA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int1989; 8: 263–268.
40.
SpronkPEBorgEJLimburgPCKallenbergCG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?Clin Exp Immunol1992; 90: 106–110.
41.
GrondalIGGunnarssonIRönnelidJ. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol2000; 18: 565–570.
42.
PetersonERobertsonADEmlenW. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus1996; 5: 571–575.
DhirVSinghAPAggarwalA. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus2009; 18: 785–791.
45.
ZhangRXingMJiX. Interferon-α and interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+ hematopoetic precursor cells. Cytokine2010; 50: 195–203.
46.
LodolceJPKolodziejLERheeL. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol2010; 184: 7001–7009.
47.
BauerJWBaechlerECPetriMBatliwallaFM. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med2006; 3: e491–e491.
